cefiderocol and Nephritis--Interstitial

cefiderocol has been researched along with Nephritis--Interstitial* in 1 studies

Other Studies

1 other study(ies) available for cefiderocol and Nephritis--Interstitial

ArticleYear
Cefiderocol treatment of Pseudomonas aeruginosa and extensively drug-resistant Acinetobacter baumannii retained spinal hardware infection causing reversible acute interstitial nephritis: Recto: Cefiderocol causing acute interstitial nephritis.
    International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2021, Volume: 109

    Infections with extensively drug-resistant Acinetobacter baumannii (XDRAB) have limited therapeutic options. We report successful salvage treatment of XDRAB and Pseudomonas aeruginosa-infected retained spinal hardware with cefiderocol, despite the development of reversible acute interstitial nephritis after 32 days of treatment.

    Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Cefiderocol; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Nephritis, Interstitial; Pharmaceutical Preparations; Pseudomonas aeruginosa

2021